Rituximab, but not other biologics, impairs humoral immunity in patients with rheumatoid arthritis-a study using CoVariant protein arrays.
Wei-Hsun LinPin-Xian DuPei-Shan TsaiBatuhan Birol KeskinWen-Yu SuNan-Yao LeeWen-Chien KoPei-Chun LinHsi-Chang ShihMeng-Yu WengGuan-Da SyuPublished in: Rheumatology advances in practice (2023)
After receiving three doses of SARS-CoV-2 vaccination, RA patients who underwent rituximab treatment generated sufficient antibodies but exhibited lower neutralizing activities against wild-type and multiple variants, including current Omicron. Other biological DMARDs, e.g. TNF inhibitor, IL-6 inhibitor and CTLA4-Ig, did not show obvious inhibition.
Keyphrases
- sars cov
- wild type
- end stage renal disease
- rheumatoid arthritis
- diffuse large b cell lymphoma
- ejection fraction
- newly diagnosed
- immune response
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- chronic lymphocytic leukemia
- hodgkin lymphoma
- dna methylation
- combination therapy
- binding protein
- rheumatoid arthritis patients
- protein protein
- systemic sclerosis
- idiopathic pulmonary fibrosis